Literature DB >> 25378567

Neutralization activity of patient sera collected during the 2008-2009 Chikungunya outbreak in Thailand.

Natsuko Kishishita1, Mikiko Sasayama2, Naokazu Takeda3, Areerat Sa-Ngasang4, Atchareeya Anuegoonpipat4, Surapee Anantapreecha4.   

Abstract

Chikungunya virus (CHIKV) infection typically causes fever, rash, myalgia, and arthralgia and sometimes results in recurrent joint pain or, in severe cases, neurological disorders or death. How CHIKV infection leads to prolonged or severe symptoms is still not well understood. In this study, we examined the neutralization (NT) titer of 98 serum samples collected from patients during the 2008-2009 chikungunya outbreak in Thailand. While all serum samples showed neutralizing activity, virus was detected in 58% of the serum samples. When we analyzed a possible association between virus and antibody titers and the presence of typical symptoms of CHIKV infection, fever and joint pain, there was no significant association except that the number of patients with fever was over three times more than the number of those without fever when CHIKV was detectable in serum. This study indicates that although neutralizing antibody is critical to eliminate CHIKV, it appears not to be the main factor associated with clinical symptoms in some cases, so that other aspects of immune responses, such as those involving proinflammatory mediators and adaptive immune cells, should be considered altogether.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25378567      PMCID: PMC4290920          DOI: 10.1128/JCM.02744-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

Review 1.  Chikungunya: a re-emerging virus.

Authors:  Felicity J Burt; Micheal S Rolph; Nestor E Rulli; Suresh Mahalingam; Mark T Heise
Journal:  Lancet       Date:  2011-11-17       Impact factor: 79.321

Review 2.  Immuno-biology of Chikungunya and implications for disease intervention.

Authors:  Yiu-Wing Kam; Edward K S Ong; Laurent Rénia; Joo-Chuan Tong; Lisa F P Ng
Journal:  Microbes Infect       Date:  2009-09-06       Impact factor: 2.700

3.  Europe on alert for flying invaders.

Authors:  Declan Butler
Journal:  Nature       Date:  2012-09-13       Impact factor: 49.962

4.  Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response.

Authors:  Jean-Jacques Hoarau; Marie-Christine Jaffar Bandjee; Pascale Krejbich Trotot; Trina Das; Ghislaine Li-Pat-Yuen; Bérengère Dassa; Mélanie Denizot; Elsa Guichard; Anne Ribera; Tawfiq Henni; Frank Tallet; Marie Pierre Moiton; Bernard Alex Gauzère; Sandrine Bruniquet; Zaïnoul Jaffar Bandjee; Philippe Morbidelli; Gérard Martigny; Michel Jolivet; Frederick Gay; Marc Grandadam; Hugues Tolou; Vincent Vieillard; Patrice Debré; Brigitte Autran; Philippe Gasque
Journal:  J Immunol       Date:  2010-04-19       Impact factor: 5.422

5.  Serious acute chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005-2006.

Authors:  Jérôme Lemant; Véronique Boisson; Arnaud Winer; Laure Thibault; Hélène André; François Tixier; Marie Lemercier; Emmanuel Antok; Marie Pierre Cresta; Philippe Grivard; Mathieu Besnard; Olivier Rollot; François Favier; Michel Huerre; José L Campinos; Alain Michault
Journal:  Crit Care Med       Date:  2008-09       Impact factor: 7.598

6.  An essential role of antibodies in the control of Chikungunya virus infection.

Authors:  Fok-Moon Lum; Teck-Hui Teo; Wendy W L Lee; Yiu-Wing Kam; Laurent Rénia; Lisa F P Ng
Journal:  J Immunol       Date:  2013-05-13       Impact factor: 5.422

7.  Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection.

Authors:  Natsuko Kishishita; Naokazu Takeda; Atchareeya Anuegoonpipat; Surapee Anantapreecha
Journal:  J Clin Microbiol       Date:  2013-02-13       Impact factor: 5.948

8.  Use of human monoclonal antibodies to treat Chikungunya virus infection.

Authors:  Jan Fric; Sébastien Bertin-Maghit; Cheng-I Wang; Alessandra Nardin; Lucile Warter
Journal:  J Infect Dis       Date:  2012-11-02       Impact factor: 5.226

Review 9.  Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia.

Authors:  Laurence Dupuis-Maguiraga; Marion Noret; Sonia Brun; Roger Le Grand; Gabriel Gras; Pierre Roques
Journal:  PLoS Negl Trop Dis       Date:  2012-03-27

10.  Genetic characterization of 2006-2008 isolates of Chikungunya virus from Kerala, South India, by whole genome sequence analysis.

Authors:  E Sreekumar; Aneesh Issac; Sajith Nair; Ramkumar Hariharan; M B Janki; D S Arathy; R Regu; Thomas Mathew; M Anoop; K P Niyas; M R Pillai
Journal:  Virus Genes       Date:  2009-10-23       Impact factor: 2.332

View more
  1 in total

1.  Post-Chikungunya Virus Infection Musculoskeletal Disorders: Syndromic Sequelae after an Outbreak.

Authors:  Hisham A Imad; Wasin Matsee; Sajikapon Kludkleeb; Punyisa Asawapaithulsert; Juthamas Phadungsombat; Emi E Nakayama; Keita Suzuki; Pornsawan Leaungwutiwong; Watcharapong Piyaphanee; Weerapong Phumratanaprapin; Tatsuo Shioda
Journal:  Trop Med Infect Dis       Date:  2021-04-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.